Biogen’s New Alzheimer’s Drug, Aduhelm, Comes With $56,000 Annual Cost
When the FDA announced on Monday that it had approved a new Alzheimer’s drug from Biogen, a biotech company based in Massachusetts, economic analysts were not enthusiastic. Though the new drug, Aduhelm, presents some hope to patients and families because it has the potential to slow early-on cognitive decline, there is not yet enough evidence to prove its actual effectiveness, at least not enough to validate its $56,000 annual cost. While its momentum comes from the fact that it is the first drug of its kind for Alzheimer’s in the past two decades, the proposed price is higher than some analys...